Genocea Biosciences Inc Buchwert je Aktie
Was ist das Buchwert je Aktie von Genocea Biosciences Inc?
Buchwert je Aktie von Genocea Biosciences Inc ist 0.00
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Genocea Biosciences Inc
Was macht Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Unternehmen mit buchwert je aktie ähnlich Genocea Biosciences Inc
- Cycliq hat Buchwert je Aktie von 0.00
- B. Riley Principal Merger II hat Buchwert je Aktie von 0.00
- FG Acquisition hat Buchwert je Aktie von 0.00
- Nexway AG hat Buchwert je Aktie von 0.00
- THC Therapeutics hat Buchwert je Aktie von 0.00
- Thoma Bravo Advantage hat Buchwert je Aktie von 0.00
- Genocea Biosciences Inc hat Buchwert je Aktie von 0.00
- Canada Rare Earth hat Buchwert je Aktie von 0.00
- Galilee hat Buchwert je Aktie von 0.00
- PT Aneka Tambang Tbk hat Buchwert je Aktie von 0.00
- Coho Collective Kitchens hat Buchwert je Aktie von 0.00
- My Rewards International Ltd hat Buchwert je Aktie von 0.00
- Six Sigma Metals hat Buchwert je Aktie von 0.00